FUBIMINA acts as a reasonably potent [[agonist]] for the [[CB2 receptor|CB<sub>2</sub> receptor]] ([[dissociation constant|''K''<sub>i</sub>]]&nbsp;=&nbsp;23.45&nbsp;nM), with 12x selectivity over [[CB1 receptor|CB<sub>1</sub>]] (''K''<sub>i</sub>&nbsp;=&nbsp;296.1&nbsp;nM), and does not fully substitute for [[Tetrahydrocannabinol|Δ<sup>9</sup>-THC]] in rat discrimination studies.<ref>{{cite journal | url=http://jpet.aspetjournals.org/content/early/2015/06/23/jpet.115.225326.short | title=AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ<sup>9</sup>-Tetrahydrocannabinol-Like Effects in Mice |author1=Jenny L Wiley |author2=Julie A Marusich |author3=Timothy W Lefever |author4=Kateland R Antonazzo |author5=Michael T Wallgren |author6=Ricardo A Cortes |author7=Purvi R Patel |author8=Megan Grabenauer |author9=Katherine N Moore |author10=Brian F Thomas | journal=Journal of Pharmacology and Experimental Therapeutics |date=June 2015  | doi=10.1124/jpet.115.225326 | pmid=26105953 | pmc=4538877 | volume=354 | pages=328–39}}</ref>
